A guide for easy- and difficult-to-treat hypertension

International Journal of Cardiology

Volumn 172, Issue 1, 2014, Pages 17-22

  Schmieder, Roland E ^a   Volpe, Massimo ^b,c   Waeber, Bernard ^d   Ruilope, Luis M ^e  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Hypertension; Renal denervation; Treatment algorithm

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ALGORITHM; HUMAN; HYPERTENSION, RENAL; PROCEDURES; SYMPATHECTOMY;

ALGORITHMS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, RENAL; SYMPATHECTOMY;

EID: 84894085155     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.12.125     Document Type: Review

References (48)

1. World Health Organization The World Health Report 2002: Reducing risks, promoting healthy life 2002 World Health Organization Geneva, Switzerland [ http://www.who.int/whr/2002/. Accessed March 1, 2013]
2. G. Mancia, R. Fagard, and K. Narkiewicz et al. ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 31 2013 1281 1357
3. W.C. Cushman, G.W. Evans, and R.P. Byington et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 2010 1575 1585
4. A. Zanchetti, G. Grassi, and G. Mancia When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal J Hypertens 27 2009 923 934
5. D.A. Calhoun, D. Jones, and S. Textor et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension 51 2008 1403 1419
6. J. Mathes, K. Kostev, A. Gabriel, O. Pirk, and R.E. Schmieder Relation of the first hypertension-associated event with medication, compliance and persistence in naïve hypertensive patients after initiating monotherapy Int J Clin Pharmacol Ther 48 2010 173 183
7. B.S. Bloom Continuation of initial antihypertensive medication after 1 year of therapy Clin Ther 20 1998 671 681
8. P.R. Conlin, W.C. Gerth, J. Fox, J.B. Roehm, and S.J. Boccuzzi Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes Clin Ther 23 2001 1999 2010
9. N.S. Breekveldt-Postma, F.J.A. Penning-van Beest, and S.J. Siiskonen et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke Curr Med Res Opin 24 2008 121 127
10. K. Schroeder, T. Fahey, and S. Ebrahim Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings Cochrane Database Syst Rev 4 2004 CD004804
11. S. Bangalore, G. Kamalakkannan, S. Parkar, and F.H. Messerli Fixed-dose combinations improve medication compliance: a meta-analysis Am J Med 120 2007 713 719
12. C.M. Dezii A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension Manag Care 9 Suppl. 2000 2 6
13. B. Waeber, M. Burnier, and H.R. Brunner Compliance with antihypertensive therapy Clin Exp Hypertens 21 1999 973 985
14. J. Caro, E. Morales, E. Gutierrez, L.M. Ruilope, and M. Praga Malignant hypertension in patients treated with vascular endothelial growth factor inhibitiors J Clin Hyertens 15 2013 215 216
15. M.R. Law, N.J. Wald, J.K. Morris, and R.E. Jordan Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials BMJ 326 2003 1427 1434
16. D.S. Wald, M. Law, J.K. Morris, J.P. Bestwick, and N.J. Wald Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials Am J Med 122 2009 290 300
17. H. Ogawa, S. Kim-Mitsuyama, K. Matsui, T. Jinnouchi, H. Jinnouchi, and K. Arakawa Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients Am J Med 125 2012 981 990
18. B. Dahlöf, P.S. Sever, and N.R. Poulter et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Lancet 366 2005 895 906
19. K. Jamerson, M.A. Weber, and G.L. Bakris et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 359 2008 2417 2428
20. A.H. Gradman, N.R. Cutler, P.J. Davis, J.A. Robbins, R.J. Weiss, and B.C. Wood Combined enalapril and felodipine extended release (ER) for systemic hypertension Am J Cardiol 79 1997 431 435
21. F.H. Messerli, S. Oparil, and Z. Feng Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension Am J Cardiol 86 2000 1182 1187
22. S.G. Chrysant, M. Melino, S. Karki, J. Lee, and R. Heyrman The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study Clin Ther 30 2008 587 604
23. T. Philipp, T.R. Smith, and R. Glazer et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension Clin Ther 29 2007 563 580
24. M. Kochar, R. Guthrie, J. Triscari, K. Kassler-Taub, and R.A. Reeves Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension Am J Hypertens 12 1999 797 805
25. G. Corrao, F. Nicotra, and A. Parodi et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice Hypertension 58 2011 566 572
26. M.R. Weir, W.A. Hsueh, and S.D. Nesbitt et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide J Clin Hypertens 13 2011 404 412
27. D.A. Calhoun, Y. Lacourcière, Y.T. Chiang, and R.D. Glazer Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial Hypertension 54 2009 32 39
28. B. Dahlöf, R.B. Devereux, and S.E. Kjeldsen et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003
29. N.S. Beckett, R. Peters, and A.E. Fletcher et al. Treatment of hypertension in patients 80 years of age or older N Engl J Med 358 2008 1887 1898
30. S. Julius, S.E. Kjeldsen, and M. Weber et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2004 2022 2031
31. S. Yusuf, K.K. Teo, and J. Pogue et al. Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559
32. FDA drug safety communication: new warning and contraindication for blood pressure medicines containing aliskiren (Tekturna). Food and Drug Administration Website http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm [Updated February 15, 2013. Accessed Feburary 27, 0013.]
33. M.D. Esler, H. Krum, and P.A. Sobotka et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial Lancet 376 2010 1903 1909
34. S. Oparil, S.A. Yarows, S. Patel, H. Fang, J. Zhang, and A. Satlin Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial Lancet 370 2007 221 229
35. N. Chapman, J. Dobson, and S. Wilson et al. Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension Hypertension 49 2007 839 845
36. J. Václavík, R. Sedlák, and M. Plachý et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial Hypertension 57 2011 1069 1075
37. B. Pitt, S.D. Anker, and D.A. Bushinsky et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial Eur Heart J 32 2011 820 828
38. B. Pitt, F. Zannad, and W.J. Remme et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
39. D.N. Juurlink, M.M. Mamdani, and D.S. Lee et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 351 2004 543 551
40. J. Segura, C. Cerezo, and J.A. Garcia-Donaire et al. Validation of a therapeutic scheme for the treatment of resistant hypertension J Am Soc Hypertens 5 2011 498 504
41. R. Schmieder, J. Redon, and G. Grassi et al. Updated ESH position paper on interventional therapy of resistant hypertension Eurointervention 9 2013 R58 R66
42. F. Mahfoud, T.F. Lüscher, and B. Andersson et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation Eur Heart J 34 2013 2149 2157
43. H. Krum, N. Barman, and M. Schlaich et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months Hypertension 57 2011 911 917
44. C. Ukena, F. Mahfoud, and I. Kindermann et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension J Am Coll Cardiol 58 2011 1176 1182
45. M.C. Brandt, F. Mahfoud, and S. Reda et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension J Am Coll Cardiol 59 2012 901 909
46. F. Mahfoud, B. Cremers, and J. Janker et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension Hypertension 60 2012 419 424
47. K. Heusser, J. Tank, and S. Engeli et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients Hypertension 55 2010 619 626
48. K. Wustmann, J.P. Kucera, and I. Scheffers et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension Hypertension 54 2009 530 536